Chromadex Corp (CDXC) 1.2900 $CDXC
ChromaDex Signs Material Transfer Agreement With Prominent Australian Research Institute for NIAGEN(TM) Research
PR Newswire - Thu Jul 31, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with Murdoch Childrens Research Institute, the preeminent child health research institute in Australia. ChromaDex will provide Murdoch Childrens Research Institute with quantities of its proprietary NIAGEN(TM) nicotinamide riboside (NR) ingredient for research use.
ChromaDex Initiates First Human Clinical Study to Confirm ChromaDex's NIAGEN(TM) Nicotinamide Riboside Will Increase NAD+
PR Newswire - Wed Jul 16, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the initiation of the first human clinical study for its patented ingredient NIAGEN(TM), the first and only commercially available form of nicotinamide riboside (NR). The study will engage the laboratory of Dr. Charles Brenner, Roy J. Carver Chair of Biochemistry and Professor of Internal Medicine at University of Iowa. Brenner, is credited with discovery of NR as a vitamin in organisms from yeast to people as published in Cell in 2004.
Nobel Laureate Roger Kornberg to Chair New ChromaDex Scientific Advisory Board
PR Newswire - Tue Jul 08, 7:20AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has appointed Nobel Laureate Roger Kornberg to Chair the Company's newly formed Scientific Advisory Board ("SAB"
.
ChromaDex to evaluate natural product libraries in research partnership with St Jude Children's Research Hospital
M2 - Fri Jun 20, 7:32AM CDT
Natural products company ChromaDex (Other OTC:CDXC) revealed on Thursday that it intends to evaluate its natural product libraries in a research based partnership with St Jude Children's Research Hospital.
ChromaDex Signs Collaboration Research Agreement with St. Jude Children's Research Hospital
PR Newswire - Thu Jun 19, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a joint collaboration agreement with St. Jude Children's Research Hospital to evaluate ChromaDex's natural product libraries.
ChromaDex Licenses Exclusive Patent Rights from Dartmouth College for Pharmaceutical Use of Nicotinamide Riboside (NR)
PR Newswire - Tue Jun 03, 5:30AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has licensed exclusive rights from Dartmouth College for several patents related to pharmaceutical use of nicotinamide riboside (NR). The new licensed patents include protection for human therapeutic uses of NR and build upon the patents licensed from Dartmouth in 2012 for other human uses and production methods of NR.
/C O R R E C T I O N -- ChromaDex Corporation/
PR Newswire - Fri May 30, 7:03PM CDT
In the news release, ChromaDex CEO to Present at the Jefferies 2014 Global Healthcare Conference, issued 30-May-2014 by ChromaDex Corporation over PR Newswire, we are advised by the company that the financial table at the end of the release should not be included. The complete, corrected release follows:
ChromaDex CEO to Present at the Jefferies 2014 Global Healthcare Conference
PR Newswire - Fri May 30, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that Frank L. Jaksch, Jr., founder and CEO of ChromaDex, will present at the Jefferies 2014 Global Healthcare Conference in New York on Tuesday, June 3, 2014, at 2:00 p.m. EDT.
ChromaDex and JQMS Announce Exclusive Sales and Marketing Agreement for GMP Compliance Services
PR Newswire - Wed May 28, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, and Joy's Quality Management Systems, Inc. (JQMS), a leading consulting firm for regulatory compliance and training services, announced today that ChromaDex has been designated as the exclusive sales and marketing agent for JQMS' services.
ChromaDex Announces Second Human Clinical Trial
ACCESSWIRE - Wed May 21, 8:28AM CDT
ChromaDex Inc. (OTCQB: CDXC) saw its share volume soar on May 20th with 224,975 shares exchanging hands, significantly higher than its three month daily average volume of 143,835 shares.
Thorne Research Introduces a New Product, NiaCel(TM), Featuring NIAGEN(TM), To Support Healthy Aging
PR Newswire - Wed Apr 02, 7:30AM CDT
Thorne Research today announced the launch of NiaCel(TM), an innovative nutritional supplement that supports endurance, energy, and healthy aging. NiaCel(TM) is one of the first commercially available products to feature the ingredient NIAGEN(TM) from ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic, and pharmaceutical industries.
ChromaDex® Reports 2013 Full-Year Results
PR Newswire - Thu Mar 27, 5:45AM CDT
ChromaDex® Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the financial results for the year ended December 28, 2013.
ChromaDex Signs Material Transfer Agreement With Leading Dutch University for NIAGEN(TM) Research
PR Newswire - Wed Mar 12, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with the Groningen Biomolecular Sciences & Biotechnology Institute (GBB), a leading research institute at the University of Groningen in the Netherlands. ChromaDex will provide GBB with quantities of its proprietary NIAGEN(TM) nicotinamide riboside (NR) ingredient.
ChromaDex to Present at the 26th Annual ROTH Conference on March 10th at 4:30 pm PDT
PR Newswire - Thu Mar 06, 7:20AM CST
ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at the 26th Annual ROTH Conference, which will take place from March 9-12 at the Ritz-Carlton Laguna Niguel in Dana Point, Calif.
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Feb 27, 8:59AM CST
RedChip Companies, Inc. ("RedChip" , an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program will feature two emerging growth companies on Fox Business nationwide on Thursday, February 27, 2014 at 10:00 p.m. Pacific (1 a.m. EST). The show will also air on Bloomberg U.K. Saturday, March 1, 2014 at 12:30 a.m. GMT; on Bloomberg Europe Sunday, March 2, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday March 2, 2014 at 3:30 p.m. HKT.
Public Outcry Over Mavuno Church "Gerrit" Poster
by Khikami Obbayi - All Africa Global Media - Wed Feb 26, 12:01AM CST
The Mavuno Church over the weekend put up a controversial poster which has been trending on Social Media as people weigh in on the debate of the appropriateness of the poster's design. The poster which is an advert for a series of sermons to be held during services for the month of March incorporates a picture of would be teens in a presumably intimate position together with titles to secular songs including a controversial book title.
ChromaDex CEO to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference on Wednesday, January 22nd at 8:30 am EST
PR Newswire - Fri Jan 17, 7:30AM CST
ChromaDex Corp.® (OTCBB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at "TEN," Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida in Room 2 on Wednesday, January 22, 2014 at 8:30 am EST.
ChromaDex CEO Frank Jaksch to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM
Marketwire - Mon Jan 06, 9:12AM CST
ChromaDex(R) Corporation (OTCBB: CDXC) ("ChromaDex" or the "Company" , an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today its CEO Frank Jaksch will be interviewed live today by Michal Yorba on Clear Channel Business Talk Radio's The Traders Network. The interview will air on Monday, January 6, 2014, at 2:45pm CST / 12:45pm PST / 3:45pm EST.
ChromaDex® Announces $62 Million Ingredient Agreement with Network Marketing Company 5LINX®
PR Newswire - Mon Jan 06, 7:30AM CST
ChromaDex Corporation® (OTCBB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a four year ingredient supply and brand licensing agreement valued at approximately $62 million, with 5LINX®, one of the largest and fastest-growing direct marketing companies in the world.
ChromaDex® Appoints Former Nestle Executive to Its Board of Directors
PR Newswire - Fri Jan 03, 7:30AM CST
ChromaDex® Corporation (OTCQB: CDXC) ("ChromaDex" or the "Company" , an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today an addition to its board of directors with the appointment of Steve Allen as an independent director.
ChromaDex Signs Material Transfer Agreement With Prominent Australian Research Institute for NIAGEN(TM) Research
PR Newswire - Thu Jul 31, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with Murdoch Childrens Research Institute, the preeminent child health research institute in Australia. ChromaDex will provide Murdoch Childrens Research Institute with quantities of its proprietary NIAGEN(TM) nicotinamide riboside (NR) ingredient for research use.
ChromaDex Initiates First Human Clinical Study to Confirm ChromaDex's NIAGEN(TM) Nicotinamide Riboside Will Increase NAD+
PR Newswire - Wed Jul 16, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the initiation of the first human clinical study for its patented ingredient NIAGEN(TM), the first and only commercially available form of nicotinamide riboside (NR). The study will engage the laboratory of Dr. Charles Brenner, Roy J. Carver Chair of Biochemistry and Professor of Internal Medicine at University of Iowa. Brenner, is credited with discovery of NR as a vitamin in organisms from yeast to people as published in Cell in 2004.
Nobel Laureate Roger Kornberg to Chair New ChromaDex Scientific Advisory Board
PR Newswire - Tue Jul 08, 7:20AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has appointed Nobel Laureate Roger Kornberg to Chair the Company's newly formed Scientific Advisory Board ("SAB"
. ChromaDex to evaluate natural product libraries in research partnership with St Jude Children's Research Hospital
M2 - Fri Jun 20, 7:32AM CDT
Natural products company ChromaDex (Other OTC:CDXC) revealed on Thursday that it intends to evaluate its natural product libraries in a research based partnership with St Jude Children's Research Hospital.
ChromaDex Signs Collaboration Research Agreement with St. Jude Children's Research Hospital
PR Newswire - Thu Jun 19, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a joint collaboration agreement with St. Jude Children's Research Hospital to evaluate ChromaDex's natural product libraries.
ChromaDex Licenses Exclusive Patent Rights from Dartmouth College for Pharmaceutical Use of Nicotinamide Riboside (NR)
PR Newswire - Tue Jun 03, 5:30AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has licensed exclusive rights from Dartmouth College for several patents related to pharmaceutical use of nicotinamide riboside (NR). The new licensed patents include protection for human therapeutic uses of NR and build upon the patents licensed from Dartmouth in 2012 for other human uses and production methods of NR.
/C O R R E C T I O N -- ChromaDex Corporation/
PR Newswire - Fri May 30, 7:03PM CDT
In the news release, ChromaDex CEO to Present at the Jefferies 2014 Global Healthcare Conference, issued 30-May-2014 by ChromaDex Corporation over PR Newswire, we are advised by the company that the financial table at the end of the release should not be included. The complete, corrected release follows:
ChromaDex CEO to Present at the Jefferies 2014 Global Healthcare Conference
PR Newswire - Fri May 30, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that Frank L. Jaksch, Jr., founder and CEO of ChromaDex, will present at the Jefferies 2014 Global Healthcare Conference in New York on Tuesday, June 3, 2014, at 2:00 p.m. EDT.
ChromaDex and JQMS Announce Exclusive Sales and Marketing Agreement for GMP Compliance Services
PR Newswire - Wed May 28, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, and Joy's Quality Management Systems, Inc. (JQMS), a leading consulting firm for regulatory compliance and training services, announced today that ChromaDex has been designated as the exclusive sales and marketing agent for JQMS' services.
ChromaDex Announces Second Human Clinical Trial
ACCESSWIRE - Wed May 21, 8:28AM CDT
ChromaDex Inc. (OTCQB: CDXC) saw its share volume soar on May 20th with 224,975 shares exchanging hands, significantly higher than its three month daily average volume of 143,835 shares.
Thorne Research Introduces a New Product, NiaCel(TM), Featuring NIAGEN(TM), To Support Healthy Aging
PR Newswire - Wed Apr 02, 7:30AM CDT
Thorne Research today announced the launch of NiaCel(TM), an innovative nutritional supplement that supports endurance, energy, and healthy aging. NiaCel(TM) is one of the first commercially available products to feature the ingredient NIAGEN(TM) from ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic, and pharmaceutical industries.
ChromaDex® Reports 2013 Full-Year Results
PR Newswire - Thu Mar 27, 5:45AM CDT
ChromaDex® Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the financial results for the year ended December 28, 2013.
ChromaDex Signs Material Transfer Agreement With Leading Dutch University for NIAGEN(TM) Research
PR Newswire - Wed Mar 12, 7:25AM CDT
ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with the Groningen Biomolecular Sciences & Biotechnology Institute (GBB), a leading research institute at the University of Groningen in the Netherlands. ChromaDex will provide GBB with quantities of its proprietary NIAGEN(TM) nicotinamide riboside (NR) ingredient.
ChromaDex to Present at the 26th Annual ROTH Conference on March 10th at 4:30 pm PDT
PR Newswire - Thu Mar 06, 7:20AM CST
ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at the 26th Annual ROTH Conference, which will take place from March 9-12 at the Ritz-Carlton Laguna Niguel in Dana Point, Calif.
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Feb 27, 8:59AM CST
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program will feature two emerging growth companies on Fox Business nationwide on Thursday, February 27, 2014 at 10:00 p.m. Pacific (1 a.m. EST). The show will also air on Bloomberg U.K. Saturday, March 1, 2014 at 12:30 a.m. GMT; on Bloomberg Europe Sunday, March 2, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday March 2, 2014 at 3:30 p.m. HKT. Public Outcry Over Mavuno Church "Gerrit" Poster
by Khikami Obbayi - All Africa Global Media - Wed Feb 26, 12:01AM CST
The Mavuno Church over the weekend put up a controversial poster which has been trending on Social Media as people weigh in on the debate of the appropriateness of the poster's design. The poster which is an advert for a series of sermons to be held during services for the month of March incorporates a picture of would be teens in a presumably intimate position together with titles to secular songs including a controversial book title.
ChromaDex CEO to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference on Wednesday, January 22nd at 8:30 am EST
PR Newswire - Fri Jan 17, 7:30AM CST
ChromaDex Corp.® (OTCBB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at "TEN," Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida in Room 2 on Wednesday, January 22, 2014 at 8:30 am EST.
ChromaDex CEO Frank Jaksch to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM
Marketwire - Mon Jan 06, 9:12AM CST
ChromaDex(R) Corporation (OTCBB: CDXC) ("ChromaDex" or the "Company"
, an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today its CEO Frank Jaksch will be interviewed live today by Michal Yorba on Clear Channel Business Talk Radio's The Traders Network. The interview will air on Monday, January 6, 2014, at 2:45pm CST / 12:45pm PST / 3:45pm EST. ChromaDex® Announces $62 Million Ingredient Agreement with Network Marketing Company 5LINX®
PR Newswire - Mon Jan 06, 7:30AM CST
ChromaDex Corporation® (OTCBB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a four year ingredient supply and brand licensing agreement valued at approximately $62 million, with 5LINX®, one of the largest and fastest-growing direct marketing companies in the world.
ChromaDex® Appoints Former Nestle Executive to Its Board of Directors
PR Newswire - Fri Jan 03, 7:30AM CST
ChromaDex® Corporation (OTCQB: CDXC) ("ChromaDex" or the "Company"
, an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today an addition to its board of directors with the appointment of Steve Allen as an independent director. 
